This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, based on findings from the SUMMIT trial.
Furthermore, obesity reduces health-related quality of life (HRQoL), an essential indicator for treatment efficacy of AF ablation. HRQoL and recurrence incidence were assessed for normal weight (BMI24.9kg/m2), overweight (25.029.9kg/m2) and obese (30.0kg/m2) patients. HRQoL was assessed at baseline and 1-year follow-up.
In today’s society, the prevalence of obesity has become a significant concern. have obesity, and this rate has increased by more than 10 percentage points in the past two decades. Understanding the prevalence of obesity is crucial in comprehending why events like Healthy Weight Week are essential. of adults in the U.S.
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Echocardiography demonstrated increased CO with obesity, but not estimated right atrial (RA) pressure or E/e′. Overall, 60.9%
Atrial fibrillation (AF) is responsible for significant patient morbidity, and obesity is a major contributor to AF incidence and symptom burden. This randomised study set out to examine if smartphone-based app technology could increase weight loss in a patient population with obesity and AF.
Overall BMI was normal, however 17% (5 of 30) were overweight or obese (Table 1).The Physical activity level includes structured sports participation, daily stepcounts, and active-zone-minute, AZM (minute spend doing activity ≥ moderate intensity) measured by accelerometer (Fitbit Inspire3).Patients The less active Fontan had higher fat% (24.8±8.7
This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We
By prioritizing cardiovascular health, individuals can improve their quality of life and longevity. Moreover, a healthy heart contributes to improved overall fitness, endurance, and quality of life. Why is cardiovascular health important?
While it’s well-known that mental health issues like anxiety and depression can profoundly impact one’s quality of life, what’s often overlooked is their potential to affect physical health, particularly the heart. Sleep deprivation is linked to inflammation, obesity, and other risk factors for heart disease.
IntroductionPatients with cognitive impairment often have a history of cardiovascular disease (CVD) or multiple cardiovascular risk factors (CRFs) such as hypertension, obesity, and hypercholesterolemia. Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023.
This clinical trial cohort included participants aged 24 to 70, with diagnosed co-morbidities that included OSA, asthma, diabetes, obesity hypertension, Heart Failure (HF) and hyperthyroidism. The achievement follows the recent announcement of Cor's capability to capture real-time, AI-enabled on-demand ejection fraction (EF).
Much of heart disease is linked to conditions like diabetes, obesity, or chronic kidney disease, and specific mutations in nucleic acids help identify them. It ultimately aims to improve outcomes and enhance the quality of life for individuals with heart-related conditions.
For over 50 years, rates of those who are overweight or obese have been rising rapidly. Despite the rise in obesity rates, the growing recognition of it as a global problem and the astronomical sums of money we spend on addressing it, the tide continues to rise. That is until now. The answer is… eye wateringly well.
Obesity is one of the world’s biggest health crisis and only seems to be getting worse. For over 50 years, the rates of obesity have continued to rise worldwide 1. The most recent data on obesity has shown a decline for the first time in a very long time. Between 2020 and 2023, the rates of obesity dropped by about 2% 2.
The 14 Factors Include: Hearing Loss High LDL cholesterol Less Education Traumatic Brain Injury Depression Social Isolation Hypertension Obesity Smoking Excess Alcohol Diabetes Physical Inactivity Air Pollution Visual Loss Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission When You Intervene Matters.
Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 5.4,16.1), 8.1 2.7,13.4), 4.6 (-0.6,9.9) 8.8), -9.4 (-11.5,-7.2),
The primary outcomes were exercise capacity, diastolic function, and quality of life at baseline evaluation. Patients studied were older (68 years old), white (90%), obese (average BMI 34 kg/m2) individuals with an average LVEF of 61%. Patients were divided into two groups based on BB use at trial enrollment.
Rivus Pharmaceuticals’ HU6 is showing promise as a future obesity-related HFpEF treatment, after topline results from its Phase 2a HuMAIN trial revealed valuable weight, symptom, and cardiometabolic improvements – without the risk of muscle loss. The post Rivus HU6 Shows Obesity-HFpEF Potential appeared first on Cardiac Wire.
Less major diseases earlier in life. Healthspan A common refrain I hear is, “ I have no interest in living longer if I do not have a good quality of life ” However, one of the single biggest factors impacting your quality of life will be whether or not you have a major chronic disease. Less diabetes.
A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity. Earlier projections had estimated that 3.3 million U.S. The study appears Sept. 11 in the Journal of the American College of Cardiology JACC.
The primary effectiveness endpoint was a composite of death, heart transplant/left ventricular assist device (LVAD) implantation, HF hospitalization, outpatient HF worsening, and quality of life. This type of HF is largely associated with obesity and hypertension. healthcare system.
Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity.
Background: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. Circulation, Ahead of Print. The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio 1.63, 95%CI, 1.17, 2.28;P=0.004).Conclusions:
By detecting and addressing heart problems early, you can reduce your risk of serious complications and improve your quality of life. At AMS Cardiology, we are dedicated to providing the highest quality care for our patients. Regular check-ups are essential for maintaining optimal heart health.
A-Fib, as the condition is commonly known, has been on the rise for at least the past decade, driven by the aging of the population, along with increasing rates of hypertension, diabetes and obesity. Earlier projections had estimated that 3.3 million U.S. The study appears Sept. 11 in the Journal of the American College of Cardiology JACC.
His techniques and protocols allow for excellent results and greatly improved quality of life. Physical Inactivity and Obesity A sedentary lifestyle and obesity are significant risk factors for heart disease. Obesity is associated with conditions like diabetes and sleep apnea, which further increase cardiovascular risk.
Background Sex differences in atrial fibrillation (AF) are observed in terms of comorbidities, symptoms, therapies received, AF progression and cardiovascular complications. Results 417 patients were included, 179 (43%) of whom were women.
In addition, participants with a consistently high adolescence‐to‐adulthood stress pattern had greater overall cardiometabolic risk, android/gynoid ratio, percent body fat, as well as greater odds of obesity in adulthood, compared to those with a consistently low PSS.
Lifestyle Habits: Obesity, smoking, excessive alcohol consumption, and lack of exercise can all negatively impact sexual function. Therapy, such as cognitive-behavioral therapy (CBT) or couples counseling, can help patients address any emotional challenges they face and improve their overall quality of life post-surgery.
For adults with overweight and obesity, resistance exercise increases lean body mass and reduces body fat percentage and fat mass — improving overall body composition. Of course, these benefits can also extend to individuals with a BMI in the normal range.
For adults with overweight and obesity, resistance exercise increases lean body mass and reduces body fat percentage and fat mass — improving overall body composition. Of course, these benefits can also extend to individuals with a BMI in the normal range.
One STEP-HFpEF trial analysis showed that patients with obesity-related HFpEF on semaglutide achieved cardiac remodeling benefits beyond the impact of weight loss. Another analysis of STEP-HFpEF suggested semaglutide decreases inflammation in patients with obesity-related HFpEF.
The Annals of Thoracic Surgery February 2022 Uma Sachdeva Contributing factors to lymph node recovery with esophagectomy by thoracic surgeons: An analysis of the Society of Thoracic Surgeons General Thoracic Surgery Database Diseases of the Esophagus January 2022 Mark Allen Bias Against Complex Lung Cancer Surgery The Annals of Thoracic Surgery December (..)
The Annals of Thoracic Surgery February 2022 Uma Sachdeva Contributing factors to lymph node recovery with esophagectomy by thoracic surgeons: An analysis of the Society of Thoracic Surgeons General Thoracic Surgery Database Diseases of the Esophagus January 2022 Mark Allen Bias Against Complex Lung Cancer Surgery The Annals of Thoracic Surgery December (..)
What better way to join the fall festivities than by spotlighting key insights in cardiorenal metabolic medicine, primary prevention, and quality of life improvements shared at this year’s biggest U.S. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues.
Our quality of life in terms of functional and cognitive capacity will decline. Yes, lots of people have risk factors, and obesity is a growing issue, but in general, the modern world is taking a proactive approach to health. Our time here is brief and will end.
A more holistic approach to maternal health has been proven to give women the best chance of a healthy pregnancy and birth, and of enjoying lasting quality of life after delivery, says the author of a new analysis on maternal death , WHO scientist Dr. Jenny Cresswell. 2325, in Boston.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content